Clinical trials: Chemotherapy Induced Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy (CIPN)
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer…
- Trial name
- NCT06994507
- Testing
- GM1
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chemotherapy Induced Peripheral Neuropathy (CIPN)
SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects
Randomized, double-bline, placebo-controlled, single dose study comparing the pharmacokinetics (PK) and safety of PP095-01 in Japanese and non-Asian (eg, Caucasian) subjects.
- Trial name
- NCT03430999
- Testing
- Calmangafodipir
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Egetis Therapeutics AB (publ)
Chemotherapy-Induced Peripheral Neuropathy
Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer
Prevention and treatment of the severity of symptoms of chemotherapy-induced peripheral neuropathy.
- Trial name
- NCT00380874
- Testing
- Pregabalin
- Where
- 15 sites in Australia, Germany and 4 more
- Volunteers
- 64 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chemotherapy-induced Peripheral Neuropathy
A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)
The primary objective of the study is: to assess the safety and tolerability of multiple oral (twice daily [BID]) doses of TRK-750 in oxaliplatin-treated colorectal cancer patients with chemotherapy-induced peripheral neuropathy…
- Trial name
- NCT04282590
- Sponsor
- Toray Industries, Inc
Locally Advanced or Metastatic Breast Cancer
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the…
- Trial name
- IRENE (NCT03027245)
- Testing
- Eribulin
- Where
- 65 sites in Germany
- Volunteers
- 353 people
- Sponsor
- Eisai GmbH
Pain, Peripheral Neuropathy
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone.
- Conditions
- Pain, Peripheral Neuropathy, Neuropathic Pain
- Trial name
- TTX-CINP-201 (NCT01655823)
- Testing
- Tetrodotoxin
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Wex Pharmaceuticals Inc.
Chemotherapy Induced Peripheral Neuropathy
Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy
Taxane -induced peripheral neuropthy (TIPN) and nail toxicites are frequent side effects of taxane therapy in breast cancer patients..
- Trial name
- TARIAN 014 (NCT07082764)
- Testing
- Brimonidine gel, No intervantion
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Tarian Pharma
Peripheral Nervous System Diseases
Pre-study to Evaluate IENFD Induction in Patients With Taxane-induced CIPN
This is a non-interventional study examining IENFD levels in patients with CIPN after taxane chemotherapy and in age-matched healthy subjects.
- Trial name
- NCT05133947
- Testing
- Non interventional
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy
Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy
This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of…
- Conditions
- Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
- Trial name
- SENSE (NCT04932031)
- Where
- 2 sites in United States
- Volunteers
- 123 people
- Sponsor
- Sapere Bio